Salman Rahman has a career in biomedical research spanning over 25 years working at some of the UK’s leading academic and biomedical research institutions. He began his research career studying the biochemistry of gap junctions at the National Institute for Medical Research (MRC) using targeted antibody technology to elucidate the structure-function of connexins leading to his PhD in 1991. Following post-doctoral posts at the Thrombosis Research Institute London and at the Centre for Thrombosis and Haemostasis at St Thomas’ Hospital, where he studied the structure-function of disintegrins, Dr Rahman was appointed as Lecturer at King’s College London between 1999-2009 where he investigated the role of the extracellular matrix and disintegrin-metalloproteinase (ADAMs) in regulating vascular cell signalling in the context of angiogenesis and cardiovascular disease. His research with colleagues during this period led to discoveries that would underpin the development of Vasgen.
Dr Rahman has published over 30 papers with esteemed colleagues from the UK, US and China and holds an Honorary Senior Lectureship in the Dept. Cell Biology at the UCL Institute of Ophthalmology. In 2011, he co-founded Vasgen, where he is currently the CEO, in order to develop novel therapeutic technologies.